RU2005137361A - ANGIOTENZINE II RECEPTOR BLOCKERS FOR THE PREVENTION OF DEVELOPMENT OR PROGRESSION OF A DIABETESMITTED MICROVASCULAR DISEASE - Google Patents

ANGIOTENZINE II RECEPTOR BLOCKERS FOR THE PREVENTION OF DEVELOPMENT OR PROGRESSION OF A DIABETESMITTED MICROVASCULAR DISEASE Download PDF

Info

Publication number
RU2005137361A
RU2005137361A RU2005137361/14A RU2005137361A RU2005137361A RU 2005137361 A RU2005137361 A RU 2005137361A RU 2005137361/14 A RU2005137361/14 A RU 2005137361/14A RU 2005137361 A RU2005137361 A RU 2005137361A RU 2005137361 A RU2005137361 A RU 2005137361A
Authority
RU
Russia
Prior art keywords
angiotensin
receptor blocker
progression
development
diabetes
Prior art date
Application number
RU2005137361/14A
Other languages
Russian (ru)
Inventor
Шоичи ЯМАГИШИ (JP)
Шоичи ЯМАГИШИ
Original Assignee
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)
Берингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE), Берингер Ингельхайм Интернациональ Гмбх filed Critical БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)
Publication of RU2005137361A publication Critical patent/RU2005137361A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Claims (11)

1. Способ предупреждения развития или прогрессирования обусловленного диабетом микрососудистого заболевания, заключающийся в том, что индивидууму, нуждающемуся в этом, вводят фармацевтически эффективное количество блокатора рецептора ангиотензина II.1. A method for preventing the development or progression of a diabetes-related microvascular disease, which method comprises administering to a subject in need of a pharmaceutically effective amount of an angiotensin II receptor blocker. 2. Способ по п.1, в котором блокатор рецептора ангиотензина II представляет собой блокатор рецептора, который ингибирует в культуре перицитов внутриклеточное образование реакционноспособных видов кислорода, индуцируемое присутствием ангиотензина II в культуральной среде.2. The method according to claim 1, wherein the angiotensin II receptor blocker is a receptor blocker that inhibits the intracellular formation of reactive oxygen species induced by the presence of angiotensin II in the culture medium in a pericyte culture. 3. Способ по п.2, в котором блокатор рецептора ангиотензина II выбран из ряда, включающего кандесартан, эпросартан, ирбесартан, лосартан, олмесартан, телмисартан и валсартан.3. The method according to claim 2, in which the angiotensin II receptor blocker is selected from the range comprising candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan and valsartan. 4. Способ по п.1, в котором предупреждают развитие или прогрессирование диабетической ретинопатии.4. The method according to claim 1, in which the development or progression of diabetic retinopathy is prevented. 5. Способ по п.1, в котором индивидуум подвержен одному или нескольким факторам риска возникновения диабета, повышенного уровня глюкозы в крови, протеинурии, повышенного уровня азота мочевины в крови, повышенного уровня креатинина в крови, микропротеинурии или системной гипертензии.5. The method according to claim 1, in which the individual is exposed to one or more risk factors for diabetes, high blood glucose, proteinuria, high blood urea nitrogen, high blood creatinine, microproteinuria or systemic hypertension. 6. Способ скрининга блокаторов рецептора ангиотензина II, предупреждающих развитие или прогрессирование микрососудистого заболевания, связанного с диабетом, заключающийся в том, что6. A method for screening angiotensin II receptor blockers to prevent the development or progression of a microvascular disease associated with diabetes, the method comprising (а) обрабатывают клетки тканевой культуры перицитов ангиотензином II или оставляют без обработки в присутствии соединения, представляющего собой потенциальный блокатор рецептора ангиотензина II или без него,(a) treating the cells of the tissue culture of pericytes with angiotensin II or leave without treatment in the presence of a compound representing a potential angiotensin II receptor blocker or without it, (б) измеряют количество образовавшихся внутри клеток реакционноспособных видов кислорода и(b) measure the amount of reactive oxygen species formed inside the cells; and (в) выявляют соединения, которые ингибируют внутриклеточное образование реакционноспособных видов кислорода, индуцированное присутствием ангиотензина II в культуральной среде.(c) detect compounds that inhibit the intracellular formation of reactive oxygen species induced by the presence of angiotensin II in the culture medium. 7. Фармацевтическая композиция для предупреждения развития или прогрессирования микрососудистого заболевания, обусловленного диабетом, такого как диабетическая ретинопатия, содержащая фармацевтически эффективное количество блокатора рецептора ангиотензина II.7. A pharmaceutical composition for preventing the development or progression of a microvascular disease due to diabetes, such as diabetic retinopathy, comprising a pharmaceutically effective amount of an angiotensin II receptor blocker. 8. Применение блокатора рецептора ангиотензина II для приготовления фармацевтической композиции для предупреждения развития или прогрессирования микрососудистого заболевания, обусловленного диабетом, такого как диабетическая ретинопатия, у индивидуума, нуждающегося в этом.8. The use of an angiotensin II receptor blocker for the preparation of a pharmaceutical composition for preventing the development or progression of a microvascular disease due to diabetes, such as diabetic retinopathy, in an individual in need thereof. 9. Применение по п.8, где блокатор рецептора ангиотензина II представляет собой блокатор рецептора, который ингибирует в культуре перицитов внутриклеточное производство реакционноспособных видов кислорода, индуцируемое присутствием ангиотензина II в культуральной среде.9. The use of claim 8, where the angiotensin II receptor blocker is a receptor blocker that inhibits in the culture of pericytes the intracellular production of reactive oxygen species induced by the presence of angiotensin II in the culture medium. 10. Применение по п.9, где блокатор рецептора ангиотензина II выбран из ряда, включающего кандесартан, эпросартан, ирбесартан, лосартан, олмесартан, телмисартан и валсартан.10. The use according to claim 9, where the angiotensin II receptor blocker is selected from the range including candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan and valsartan. 11. Применение по п.8, где индивидуум подвержен одному или нескольким факторам риска возникновения диабета, повышенного уровня глюкозы в крови, протеинурии, повышенного уровня азота мочевины в крови, повышенного уровня креатинина в крови, микропротеинурии или системной гипертензии.11. The use of claim 8, where the individual is exposed to one or more risk factors for diabetes, high blood glucose, proteinuria, high blood urea nitrogen, high blood creatinine, microproteinuria or systemic hypertension.
RU2005137361/14A 2003-05-02 2004-04-30 ANGIOTENZINE II RECEPTOR BLOCKERS FOR THE PREVENTION OF DEVELOPMENT OR PROGRESSION OF A DIABETESMITTED MICROVASCULAR DISEASE RU2005137361A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319592.0 2003-05-02
DE10319592A DE10319592A1 (en) 2003-05-02 2003-05-02 Treatment of diabetic retinopathy with angiotensin II receptor blockers

Publications (1)

Publication Number Publication Date
RU2005137361A true RU2005137361A (en) 2006-07-27

Family

ID=33305091

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005137361/14A RU2005137361A (en) 2003-05-02 2004-04-30 ANGIOTENZINE II RECEPTOR BLOCKERS FOR THE PREVENTION OF DEVELOPMENT OR PROGRESSION OF A DIABETESMITTED MICROVASCULAR DISEASE

Country Status (12)

Country Link
EP (1) EP1622607A1 (en)
JP (1) JP2006525269A (en)
KR (1) KR20060009288A (en)
CN (1) CN1784225A (en)
AU (1) AU2004233597A1 (en)
BR (1) BRPI0409853A (en)
CA (1) CA2524248A1 (en)
DE (1) DE10319592A1 (en)
MX (1) MXPA05011760A (en)
RU (1) RU2005137361A (en)
WO (1) WO2004096211A1 (en)
ZA (1) ZA200508263B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812770B2 (en) 2006-08-29 2010-10-12 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods
WO2009087900A1 (en) * 2008-01-11 2009-07-16 Daiichi Sankyo Company, Limited Pharmaceutical agent for prevention or treatment of diseases accompanied by intraocular vascular hyperpermeability
JP5860210B2 (en) * 2010-12-07 2016-02-16 株式会社オフテクス Composition for promoting lacrimal secretion containing at least one of telmisartan and losartan, an angiotensin II receptor antagonist, and a preparation for oral administration containing lacrimal secretion containing the composition
KR102233673B1 (en) * 2016-01-27 2021-03-30 보령제약 주식회사 Pharmaceutical composition for preventing or treating diabetic nephropathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
WO2002015935A1 (en) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Fibrinogen lowering agents
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt

Also Published As

Publication number Publication date
MXPA05011760A (en) 2006-01-26
DE10319592A1 (en) 2004-11-18
AU2004233597A1 (en) 2004-11-11
CN1784225A (en) 2006-06-07
JP2006525269A (en) 2006-11-09
CA2524248A1 (en) 2004-11-11
KR20060009288A (en) 2006-01-31
ZA200508263B (en) 2007-02-28
WO2004096211A1 (en) 2004-11-11
BRPI0409853A (en) 2006-05-16
EP1622607A1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
CA2904447C (en) Therapy for complications of diabetes
US9387249B2 (en) Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
JP2005533023A5 (en)
Ptinopoulou et al. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review
Rodgers et al. Angiotensin II-receptor blockers: clinical relevance and therapeutic role
TWI458722B (en) Dopamine-β-hydroxylase inhibitors, process for preparing them, pharmaceutical composition comprising the same and use thereof
WO2007098390A2 (en) Method for treating resistant hypertension
US20210121492A1 (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20090221656A1 (en) Drug Combinations
Ono et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension
Hjermitslev et al. Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension
US20090221549A1 (en) Antihypertensive therapy
Kosugi et al. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists
FR2735365A1 (en) USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS
RU2005137361A (en) ANGIOTENZINE II RECEPTOR BLOCKERS FOR THE PREVENTION OF DEVELOPMENT OR PROGRESSION OF A DIABETESMITTED MICROVASCULAR DISEASE
EP3132803A2 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
Narita et al. Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model
Kirch et al. Comparison of angiotensin II receptor antagonists
Ishimitsu et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases
Unger Pharmacological aspects of candesartan, an effective AT1-receptor blocker
Jacobi et al. Nephroprotection by antihypertensive therapy
Ishimitsu et al. Benazepril slows progression of renal dysfunction in patients with non‐diabetic renal disease
Small Antihypertensive drugs
Konoshita et al. A CROSS-OVER COMPARISON OF ANTI-ALBUMINURIC EFFECTS AMONG 4 TYPES CALCIUM CHANNEL BLOCKERS ON CHRONIC KIDNEY DISEASE: PP. 33.310
Strauch et al. NON-COMPLIANCE TO THERAPY AS A FREQUENT CAUSE OF RESISTANT HYPERTENSION–HOW COMMON AND HOW TO DETECT IT?: PP. 33.309

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090402